Literature DB >> 9286756

Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.

P Garnero1, C Fledelius, E Gineyts, C M Serre, E Vignot, P D Delmas.   

Abstract

In Paget's disease of bone, the normal lamellar bone is replaced by a woven structure with an irregular arrangement of collagen fibers. In this study, we investigated whether the degree of beta-isomerization within C-telopeptide of alpha 1 chain of type I collagen was altered in Paget's disease compared with other bone diseases with no alteration of bone structure. In Paget's disease (n = 26), but not in patients with primary hyperparathyroidism (n = 6) or hyperthyroidism (n = 17), the urinary excretion of nonisomerized (alpha) fragments derived from degradation of type I collagen C-telopeptide (CTX) was markedly increased compared with beta-isomerized CTX (+ 13-fold vs. + 3.5-fold over controls) resulting in an urinary alpha CTX/beta CTX ratio 3-fold higher than in controls (2.6 +/- 1.0 vs. 0.8 +/- 0.3, p < 0.001). In five pagetic patients in complete remission, as demonstrated by normal total alkaline phosphatase activity, the alpha CTX/beta CTX ratio was normal. The immunohistochemistry of normal and pagetic human bone sections showed a preferential distribution of alpha CTX within woven structure, while lamellar bone was intensely stained with an anti-beta CTX antibody, suggesting a lower degree of beta-isomerization of type I collagen in the woven pagetic bone. In collagenase digest of human bone specimens, we found a lower proportion of beta-isomerized type I collagen molecules in pagetic bone (40% of beta CTX) than in normal bone taken from trabecular (68%) and cortical compartments (71%). In conclusion, we found that in Paget's disease the alpha CTX/beta CTX ratio in bone and in urine is markedly increased. This altered beta isomerization can be accurately detected in vivo by measuring urinary degradation products arising from bone resorption.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286756     DOI: 10.1359/jbmr.1997.12.9.1407

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  19 in total

Review 1.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 2.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Authors:  Serge Cremers; Patrick Garnero
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  The role of collagen in bone strength.

Authors:  S Viguet-Carrin; P Garnero; P D Delmas
Journal:  Osteoporos Int       Date:  2005-12-09       Impact factor: 4.507

Review 5.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

6.  Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover.

Authors:  E Gineyts; P A Cloos; O Borel; L Grimaud; P D Delmas; P Garnero
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

7.  Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.

Authors:  P A Cloos; C Fledelius
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

8.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

Review 9.  Predicting protein decomposition: the case of aspartic-acid racemization kinetics.

Authors:  M J Collins; E R Waite; A C van Duin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-01-29       Impact factor: 6.237

Review 10.  The contribution of collagen crosslinks to bone strength.

Authors:  Patrick Garnero
Journal:  Bonekey Rep       Date:  2012-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.